u/customs_seizure_sid

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

A report is useful here when it carries dates, the exact domain, what was requested, what arrived and what did not. Everything else is atmosphere.

What is the waist doing? That is usually the number still moving during a scale stall.

Sceptical of the mechanism you are proposing. Gastric emptying slows, it does not stop, and the timings you describe do not follow from it.

2.4 is a ceiling, not a target

do not chase somebody else’s titration schedule, they are not you

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

That figure is the 68-week trial mean, not a weekly rate. Dividing it by the weeks gives you a number that does not mean anything.

Address redacted from the screenshot above. Post the wording of the notice, never the header.

Switching from semaglutide, since three people asked in this thread alone.

There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.

None of that is a recommendation. It is what the threads say, and the threads are not a clinic.

Left up. It names both countries and quotes the notice, which is exactly what makes these threads useful.

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

Push back: "nobody has tested them" is a fact about this board, not a fact about the company.

This is the check that catches most of it, and it takes under a minute.

the review page nobody can find on any other site is a warning

Adding the practical version: buy small from anyone new, test it, then decide.

I would not read across from the obesity programmes. Different population, different endpoint, different question.

Which country, and which country did it ship from?

The confounding problem, stated plainly, because this board keeps stepping on it.

Substantial weight loss moves lipids, liver enzymes, insulin sensitivity markers and several others in its own right. If you are losing weight while taking something, any change in those markers has at least two candidate explanations and you cannot separate them from your own panel.

What you can do is standardise, take a baseline, keep the series long, and be honest in your posts about what is and is not attributable. The threads that say "this compound did X to my eGFR" almost never have the design to support the claim, mine included.

nausea that arrives on day two and fades by day four is the standard shape

The site had a decade of testimonials and a domain registered in March. That was the entire investigation.

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

Nobody here can interpret your panel and this comment is not doing so. What a board can usefully do is help you ask better questions of somebody who can.

Left up. It names both countries and quotes the notice, which is exactly what makes these threads useful.

FLOW was kidney outcomes and it is the one nobody quotes

research-use-only labelling is not a customs category

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

Same. I sat at 0.5mg for three months because it was working and there was nothing to fix.

Why so many single values look alarming and turn out to be nothing.

A reference interval is built to contain about 95% of a healthy reference population, so one test in twenty falls outside one by construction. Add biological variation, assay imprecision, fasting state and time of day, and a genuinely stable person will produce occasional out-of-range results.

That is why repeat testing before acting is standard. Regression to the mean handles most of it. None of which means an out-of-range value should be ignored — it means it should be repeated and taken to somebody who can put it in context, which is emphatically not a ranked feed.

Country added to the title. Without it the answers will be confidently wrong.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

this board is small because the compound is early

Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.

A hold, a request for information and a seizure are distinct administrative events. Each has its own process and deadlines, and the notice itself states which one you have.

Pointing this one at somebody qualified locally. Nothing on this board is legal advice.

have the conversation with a clinician before, not after

Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.

Yes — describe the sequence of events with dates. That is a report. Adjectives are not.

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.